KEYONTE-522: Exploratory Biomarker Analysis in Periop Pembro vs. Placebo + Chemo

Opinion
Video

Panelists discuss the exploratory biomarker analysis from the KEYNOTE-522 trial, comparing perioperative pembrolizumab versus placebo plus chemotherapy in early-stage breast cancer, and its implications for treatment strategies.

Recent Videos
Hope S. Rugo, MD, FASCO, is featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.
Related Content